Brian Shuch, MD, of UCLA Health, previews his upcoming sessions at Urology on the Beach 2025, taking place January 17, 2025, to January 19, 2025, at the Fontainebleau Miami Beach. This comprehensive event covers all aspects of urology with presentations from leading experts in the field. Dr. Shuch’s presentation will cover the use of molecular imaging agents and their role in risk stratification and informed treatment decisions. ...
Renal Cell Carcinoma Diagnostics
Advertisement
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Machine learning models can help with clinical decision making regarding renal function, according to new data.
[⁸⁹Zr]Zr-girentuximab PET-CT ccRCC prognostic imaging has a favorable safety profile and is highly accurate.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
Researchers evaluated the tissue samples of 126 treatment-naïve patients collected from a multicenter database.
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
Advertisement
Video Insights
Conferene Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Section Editor
Daniel Joyce, MDDepartment of Urology | Vanderbilt University Medical Center
Get the latest RCC research straight to your inbox.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.